MedTrace Logo

Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

NCT03551002 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2021-09-05

No results posted yet for this study

Summary

A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Conditions

  • Hepatitis C
  • Hepatitis C, Chronic
  • HIV/AIDS

Sponsors & Collaborators

Principal Investigators

  • Edward Cachay, MD, MAS · University of California, San Diego

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03551002 on ClinicalTrials.gov